1. Adriaansen, H.J., te Boekhorst, P.A., Hagemeijer, A.M., van der Schoot, C.E., Delwel, H.R. & van Dongen, J.J. (1993). Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(pl3q22) exhibits a specific immunophenotype with CD2 expression.Blood, 81, 3043–51.
2. Béné, M.C., Castoldi, G., Knapp, W., Ludwig, W.D., Matutes, E., Orfao, A. & van’t Veer, M.B. (1995). Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).Leukemia, 9, 1783–6.
3. Creutzig, U., Harbott, J., Sperling, C., Ritter, J., Zimmermann, M., Löffler, H., Riehm, H., Schellong, G.& Ludwig, W.D. (1995). Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87.Blood, 86, 3097–108.
4. Dumont, C., Deas, O., Mollereau, B., Hebib, C., Giovino Barry, V., Bernard, A., Hirsch, F., Charpentier, B.& Senik, A. (1998). Potent apoptotic signaling and subsequent unresponsiveness induced by a single CD2 mAb (BTI-322) in activated human peripheral T cells.J Immunol 160,3797–804.
5. Houghton, J.A. (1999). Apoptosis and drug response.Curr Opin Oncol, 11, 475–81.